The next generation of CAR-T and bispecific therapies is expanding rapidly—moving beyond academic medical centers into community and outpatient settings. But while the science has accelerated, many hematologists say the operational playbook hasn’t caught up.
In this discussion, our CMO, Dr. Matt Wilkes will be joined by Dr. Sridevi Rajeeve and Dr. Neha Korde, both hematologists on the front lines of advancing outpatient advanced therapy delivery at Memorial Sloan Kettering. They’ll share how they’re rethinking delivery models, safety monitoring, and workforce readiness to bring advanced therapies to more patients without compromising safety or sustainability.